{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:27:39Z","timestamp":1768548459825,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-002562"],"award-info":[{"award-number":["INV-002562"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PP00P3_203450"],"award-info":[{"award-number":["PP00P3_203450"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The clinical development of novel vaccines, injectable therapeutics, and oral chemoprevention drugs has the potential to deliver significant advancements in the prevention of <jats:italic>Plasmodium falciparum<\/jats:italic> malaria. These innovations could support regions in accelerating malaria control, transforming existing intervention packages by supplementing interventions with imperfect effectiveness or offering an entirely new tool. However, to layer new medical tools as part of an existing programme, malaria researchers must come to an agreement on the gaps that currently limit the effectiveness of medical interventions for moderate to low transmission settings. In this perspective, three crucial gaps that may prevent new therapeutics from being used to their fullest extent are presented. First, do burden reduction outcomes, which are typically monitored in studies of new medical products, sufficiently capture the broader goal of accelerating malaria control? Layering novel malaria products requires monitoring health outcomes that reflect the novel product\u2019s targeted stage of the parasite life cycle, in addition to all-infection and prevalence-based outcomes. Second, what public health outcome does a novel medical prevention tool provide that existing malaria interventions cannot fully deliver? Novel medical tools should be developed not just for an incremental improvement in preventive efficacy over an existing product, but also to meet a gap in protection. Specifically, this means designing products with components that target parts of the parasite life cycle beyond the scope of existing therapeutics, and better addressing populations and settings not well covered by existing tools. Finally, when do the population-level benefits of a multi-tool prevention programme justify the individual-level outcomes from receiving multiple interventions? An individual-level perspective should be key for exploring when and how layering a novel prevention intervention can accelerate efforts towards <jats:italic>P. falciparum<\/jats:italic> malaria control.<\/jats:p>","DOI":"10.1186\/s12936-024-05222-4","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T19:41:58Z","timestamp":1736797318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic development to accelerate malaria control through intentional intervention layering"],"prefix":"10.1186","volume":"24","author":[{"given":"Lydia","family":"Braunack-Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narimane","family":"Nekkab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Malinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherrie L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Ansah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg J.","family":"Moehrle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Penny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"5222_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12936-023-04473-x","volume":"22","author":"KP Paaijmans","year":"2023","unstructured":"Paaijmans KP, Lobo NF. Gaps in protection: the actual challenge in malaria elimination. Malar J. 2023;22:46.","journal-title":"Malar J"},{"key":"5222_CR2","doi-asserted-by":"publisher","first-page":"8976","DOI":"10.1038\/s41467-024-53065-z","volume":"15","author":"PA Hancock","year":"2024","unstructured":"Hancock PA, North A, Leach AW, Winskill P, Ghani AC, Godfray HCJ, et al. The potential of gene drives in malaria vector species to control malaria in African environments. Nat Commun. 2024;15:8976.","journal-title":"Nat Commun"},{"key":"5222_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12936-019-2956-y","volume":"18","author":"JM Cohen","year":"2019","unstructured":"Cohen JM. \u201cRemarkable solutions to impossible problems\u201d: lessons for malaria from the eradication of smallpox. Malar J. 2019;18:323.","journal-title":"Malar J"},{"key":"5222_CR4","doi-asserted-by":"publisher","DOI":"10.30875\/9789287074102","volume-title":"World Malaria Report 2023","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. World Malaria Report 2023. Geneva: World Health Organization; 2024."},{"key":"5222_CR5","unstructured":"Mackay IM. The Swiss Cheese Respiratory Virus Defence https:\/\/figshare.com\/articles\/figure\/The_Swiss_Cheese_Respiratory_Virus_Defence\/13082618\/26. Accessed 6 Aug 2024"},{"key":"5222_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PTS.0000000000000810","volume":"18","author":"DA Wiegmann","year":"2022","unstructured":"Wiegmann DA, Wood LJ, Cohen TN, Shappell SA. Understanding the \u201cSwiss Cheese Model\u201d and its application to patient safety. J Patient Saf. 2022;18:119\u201323.","journal-title":"J Patient Saf"},{"key":"5222_CR7","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1126\/science.318.5856.1544","volume":"318","author":"L Roberts","year":"2007","unstructured":"Roberts L, Malaria Enserink M. Did they really say ... eradication? Science. 2007;318:1544\u20135.","journal-title":"Science"},{"key":"5222_CR8","unstructured":"Bill & Melinda Gates Foundation. Gates Foundation Commits $258.3 Million for Malaria Research and Development https:\/\/www.gatesfoundation.org\/ideas\/media-center\/press-releases\/2005\/10\/gates-foundation-commits-2583-million-for-malaria-research. Accessed 5 Jun 2024"},{"key":"5222_CR9","unstructured":"Bill & Melinda Gates Foundation. Bill & Melinda Gates Foundation Announces $50 Million Contribution to the Global Fund to Fight AIDS, TB, and Malaria https:\/\/www.gatesfoundation.org\/ideas\/media-center\/press-releases\/2004\/07\/50-million-to-the-global-fund-to-fight-aids-tb-and-malaria. Accessed 5 Jun 2024"},{"key":"5222_CR10","unstructured":"US Agency For International Development. The President\u2019s Malaria Initiative: Fifth Annual Report to Congress [Internet]. Washington DC: U.S. Agency for International Development 2011. Available from: https:\/\/2017-2020.usaid.gov\/open\/presidents-malaria-initiative\/2010"},{"key":"5222_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1478-4505-9-33","volume":"9","author":"RT Mahoney","year":"2011","unstructured":"Mahoney RT. Product development partnerships: case studies of a new mechanism for health technology innovation. Health Res Policy Syst. 2011;9:33.","journal-title":"Health Res Policy Syst"},{"key":"5222_CR12","unstructured":"Medicines for Malaria Venture. Our history https:\/\/www.mmv.org\/our-history. Accessed 12 Sep 2024"},{"key":"5222_CR13","unstructured":"PATH. The PATH Malaria Vaccine Initiative: Fact Sheet https:\/\/media.path.org\/documents\/MVI_backgrounder_fs_2017.pdf. Accessed 12 Sep 2024"},{"key":"5222_CR14","unstructured":"IVCC. About IVCC https:\/\/www.ivcc.com\/about\/. Accessed 12 Sep 2024"},{"key":"5222_CR15","unstructured":"FIND. About us https:\/\/www.finddx.org\/about-us\/. Accessed 12 Sep 2024"},{"key":"5222_CR16","unstructured":"World Health Organization. WHO recommends groundbreaking malaria vaccine for children at risk https:\/\/www.who.int\/news\/item\/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk. Accessed 6 Aug 2024"},{"key":"5222_CR17","unstructured":"World Health Organization. R21\/Matrix-M malaria vaccine: evidence to recommendations framework, 2023 https:\/\/www.who.int\/publications\/m\/item\/r21-matrix-m-malaria-vaccine--evidence-to-recommendations-framework--2023. Accessed 12 Sep 2024"},{"key":"5222_CR18","volume-title":"Framework for the allocation of limited malaria vaccine supply","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Framework for the allocation of limited malaria vaccine supply. Geneva: World Health Organization; 2022."},{"key":"5222_CR19","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1016\/j.vaccine.2023.04.011","volume":"41","author":"HM Topazian","year":"2023","unstructured":"Topazian HM, Schmit N, Gerard-Ursin I, Charles GD, Thompson H, Ghani AC, et al. Modelling the relative cost-effectiveness of the RTS, S\/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis. Vaccine. 2023;41:3215\u201323.","journal-title":"Vaccine"},{"key":"5222_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa2034031","volume":"385","author":"MR Gaudinski","year":"2021","unstructured":"Gaudinski MR, Berkowitz NM, Idris AH, Coates EE, Holman LA, Mendoza F, et al. A monoclonal antibody for malaria prevention. N Engl J Med. 2021;385:803\u201314.","journal-title":"N Engl J Med"},{"key":"5222_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2203067","volume":"387","author":"RL Wu","year":"2022","unstructured":"Wu RL, Idris AH, Berkowitz NM, Happe M, Gaudinski MR, Buettner C, et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N Engl J Med. 2022;387:397\u2013407.","journal-title":"N Engl J Med"},{"key":"5222_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/13543776.2023.2190884","volume":"33","author":"M Quagliata","year":"2023","unstructured":"Quagliata M, Papini AM, Rovero P. Malaria vaccines. Expert Opin Ther Pat. 2023;33:169\u201378.","journal-title":"Expert Opin Ther Pat"},{"key":"5222_CR23","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ymthe.2022.04.001","volume":"30","author":"M Aleshnick","year":"2022","unstructured":"Aleshnick M, Florez-Cuadros M, Martinson T, Wilder BK. Monoclonal antibodies for malaria prevention. Mol Ther. 2022;30:1810\u201321.","journal-title":"Mol Ther"},{"key":"5222_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S1473-3099(23)00268-2","volume":"23","author":"A Olotu","year":"2023","unstructured":"Olotu A, Moehrle JJ. Moving seasonal malaria chemoprevention out of its geographical isolation. Lancet Infect Dis. 2023;23:1102\u20133.","journal-title":"Lancet Infect Dis"},{"key":"5222_CR25","unstructured":"Medicines for Malaria Venture. MMV\u2019s pipeline of antimalarial drugs https:\/\/www.mmv.org\/mmv-pipeline-antimalarial-drugs. Accessed 6 Aug 2024"},{"key":"5222_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","volume":"385","author":"D Chandramohan","year":"2021","unstructured":"Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021;385:1005\u201317.","journal-title":"N Engl J Med"},{"key":"5222_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1473-3099(23)00368-7","volume":"24","author":"A Dicko","year":"2024","unstructured":"Dicko A, Ouedraogo JB, Zongo I, Sagara I, Cairns M, Yerbanga RS, et al. Seasonal vaccination with RTS, S\/AS01(E) vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect Dis. 2024;24:75\u201386.","journal-title":"Lancet Infect Dis"},{"key":"5222_CR28","unstructured":"US Agency For International Development . The impact of a combination of the RTS,S\/ASO1E malaria vaccine and perennial malaria chemoprevention in Ghanaian children https:\/\/insightsmalaria.org\/active-research\/posts\/rtss-vaccine-and-pmc-in-ghanaian-children. Accessed 6 Aug 2024"},{"key":"5222_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12936-022-04099-5","volume":"21","author":"M Runge","year":"2022","unstructured":"Runge M, Thawer SG, Molteni F, Chacky F, Mkude S, Mandike R, et al. Sub-national tailoring of malaria interventions in Mainland Tanzania: simulation of the impact of strata-specific intervention combinations using modelling. Malar J. 2022;21:92.","journal-title":"Malar J"},{"key":"5222_CR30","doi-asserted-by":"publisher","first-page":"238146831986134","DOI":"10.1177\/2381468319861346","volume":"4","author":"C Sauboin","year":"2019","unstructured":"Sauboin C, Van Vlaenderen I, Van Bellinghen LA, Standaert B. Reducing malaria mortality at the lowest budget: an optimization tool for selecting malaria preventative interventions applied to Ghana. MDM Policy Pract. 2019;4:2381468319861346.","journal-title":"MDM Policy Pract"},{"key":"5222_CR31","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2214-109X(16)30073-0","volume":"4","author":"PGT Walker","year":"2016","unstructured":"Walker PGT, Griffin JT, Ferguson NM, Ghani AC. Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study. Lancet Glob Health. 2016;4:e474\u201384.","journal-title":"Lancet Glob Health"},{"key":"5222_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2016-000090","volume":"2","author":"P Winskill","year":"2017","unstructured":"Winskill P, Walker PGT, Griffin JT, Ghani AC. Modelling the cost-effectiveness of introducing the RTS, S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa. BMJ Glob Health. 2017;2: e000090.","journal-title":"BMJ Glob Health"},{"key":"5222_CR33","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(21)02499-5","volume":"399","author":"JF Mosha","year":"2022","unstructured":"Mosha JF, Kulkarni MA, Lukole E, Matowo NS, Pitt C, Messenger LA, et al. Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial. Lancet. 2022;399:1227\u201341.","journal-title":"Lancet"},{"key":"5222_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","volume":"387","author":"MA Penny","year":"2016","unstructured":"Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. Public health impact and cost-effectiveness of the RTS, S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387:367\u201375.","journal-title":"Lancet"},{"key":"5222_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1473-3099(23)00816-2","volume":"24","author":"N Schmit","year":"2024","unstructured":"Schmit N, Topazian HM, Natama HM, Bellamy D, Traor\u00e9 O, Som\u00e9 MA, et al. The public health impact and cost-effectiveness of the R21\/Matrix-M malaria vaccine: a mathematical modelling study. Lancet Infect Dis. 2024;24:465\u201375.","journal-title":"Lancet Infect Dis"},{"key":"5222_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12936-023-04500-x","volume":"22","author":"D Musoke","year":"2023","unstructured":"Musoke D, Atusingwize E, Namata C, Ndejjo R, Wanyenze RK, Kamya MR. Integrated malaria prevention in low- and middle-income countries: a systematic review. Malar J. 2023;22:79.","journal-title":"Malar J"},{"key":"5222_CR37","unstructured":"Gavi the Vaccine Alliance . Vaccine Investment Strategy 2024 https:\/\/www.gavi.org\/our-alliance\/strategy\/vaccine-investment-strategy-2024. Accessed 6 Aug 2024"},{"key":"5222_CR38","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41467-021-21775-3","volume":"12","author":"JD Challenger","year":"2021","unstructured":"Challenger JD, Olivera Mesa D, Da DF, Yerbanga RS, Lefevre T, Cohuet A, et al. Predicting the public health impact of a malaria transmission-blocking vaccine. Nat Commun. 2021;12:1494.","journal-title":"Nat Commun"},{"key":"5222_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12916-022-02536-5","volume":"20","author":"M Cairns","year":"2022","unstructured":"Cairns M, Barry A, Zongo I, Sagara I, Yerbanga SR, Diarra M, et al. The duration of protection against clinical malaria provided by the combination of seasonal RTS, S\/AS01(E) vaccination and seasonal malaria chemoprevention versus either intervention given alone. BMC Med. 2022;20:352.","journal-title":"BMC Med"},{"key":"5222_CR40","volume-title":"WHO guidelines for malaria - 16 October 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. WHO guidelines for malaria - 16 October 2023. Geneva: World Health Organization; 2023."},{"key":"5222_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12936-023-04657-5","volume":"22","author":"CS Merle","year":"2023","unstructured":"Merle CS. RTSS-SMC working group, Implementation strategies for the introduction of the RTS, S\/AS01 (RTS, S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report. Malar J. 2023;22:242.","journal-title":"Malar J"},{"key":"5222_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-014719","author":"CB Osoro","year":"2024","unstructured":"Osoro CB, Ochodo E, Kwambai TK, Otieno JA, Were L, Sagam CK, et al. Policy uptake and implementation of the RTS, S\/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. BMJ Glob Health. 2024. https:\/\/doi.org\/10.1136\/bmjgh-2023-014719.","journal-title":"BMJ Glob Health"},{"key":"5222_CR43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1186\/s12879-019-4467-4","volume":"19","author":"F Camponovo","year":"2019","unstructured":"Camponovo F, Ockenhouse CF, Lee C, Penny MA. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. BMC Infect Dis. 2019;19:920.","journal-title":"BMC Infect Dis"},{"key":"5222_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12936-022-04137-2","volume":"21","author":"M El Gaaloul","year":"2022","unstructured":"El Gaaloul M, Tornesi B, Lebus F, Reddy D, Kaszubska W. Re-orienting anti-malarial drug development to better serve pregnant women. Malar J. 2022;21:121.","journal-title":"Malar J"},{"key":"5222_CR45","volume-title":"Technical consultation on the malaria rebound phenomenon Report on a virtual meeting","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Technical consultation on the malaria rebound phenomenon Report on a virtual meeting. Geneva: World Health Organization; 2022."},{"key":"5222_CR46","volume-title":"Initiative to stop the spread of Anopheles stephensi in Africa 2023 update","author":"WHO","year":"2023","unstructured":"WHO. Initiative to stop the spread of Anopheles stephensi in Africa 2023 update. Geneva: World Health Organization; 2023."},{"key":"5222_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12936-023-04690-4","volume":"22","author":"J Okyere","year":"2023","unstructured":"Okyere J, Bediako VB, Ackah JA, Acheampong E, Owusu BA, Agbemavi W, et al. RTS, S\/AS01(E) vaccine defaults in Ghana: a qualitative exploration of the perspectives of defaulters and frontline health service providers. Malar J. 2023;22:260.","journal-title":"Malar J"},{"key":"5222_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000211","volume":"2","author":"L Burgert","year":"2022","unstructured":"Burgert L, Reiker T, Golumbeanu M, Moehrle JJ, Penny MA. Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention. PLoS Glob Public Health. 2022;2: e0000211.","journal-title":"PLoS Glob Public Health"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-05222-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T19:42:04Z","timestamp":1736797324000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-05222-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5222"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-05222-4","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}